Add-On Tirzepatide May Reduce MACE Risk in People With T2D, ASCVD

FRIDAY, Aug. 7, 2026-- For individuals with type 2 diabetes and atherosclerotic cardiovascular disease, adding tirzepatide to standard-of-care treatment is associated with a reduction in the risk for major adverse cardiovascular events (MACE)...